High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV

Diabetologia

Volumn 55, Issue 1, 2012, Pages 236-244

  Marchetti, C ^a   Di Carlo, A ^a   Facchiano, F ^b   Senatore, C ^b   De Cristofaro, R ^a,c   Luzi, A ^d   Federici, M ^d   Romani, M ^a   Napolitano, M ^a   Capogrossi, M C ^a   Germani, A ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Basic science; Cells; Cytokines; Endothelium; Macrovascular complications; Oral pharmacological

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; HIGH MOBILITY GROUP B1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME SUBSTRATE; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELL MIGRATION ASSAYS; CELL MOVEMENT; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EPITOPES; FEMALE; HMGB1 PROTEIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROTEOLYSIS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84856713524     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2213-6     Document Type: Article

References (36)

1. Durinx C, Lambeir AM, Bosmans E et al (2000) Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of XProdipeptides. Eur J Biochem 267: 5608-5613
2. Yazbeck R, Howarth GS, Abbott CA (2009) Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?Trends Pharmacol Sci 30: 600-607
3. Nauck MA (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124(1 Suppl): S3-S18
4. Klune JR, Dhupar R, Cardinal J et al (2008) HMGB1: endogenous danger signaling. Mol Med 14: 476-484
5. Treutiger CJ, Mullins GE, Johansson AS et al (2003) High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 254: 375-385 (Pubitemid 37211261)
6. Fiuza C, Bustin M, Talwar S et al (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101: 2652-2660 (Pubitemid 36857626)
7. Mitola S, Belleri M, Urbinati C et al (2006) Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 176: 12-15 (Pubitemid 43023243)
8. Schlueter C, Weber H, Meyer B et al (2005) Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 166: 1259-1263 (Pubitemid 40524448)
9. De Mori R, Straino S, Di Carlo A et al (2007) Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arterioscler Thromb Vasc Biol 27: 2377-2383 (Pubitemid 350203953)
10. Chavakis E, Hain A, Vinci M et al (2007) High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 100: 204-212 (Pubitemid 46208720)
11. Palumbo R, Sampaolesi M, de Marchis F et al (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164: 441-449 (Pubitemid 38174771)
12. Straino S, Di Carlo A, Mangoni A et al (2008) High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol 128: 1545-1553 (Pubitemid 351693201)
13. Straino S, Germani A, Di Carlo A et al (2004) Enhanced arteriogenesis and wound repair in dystrophin-deficient mdx mice. Circulation 110: 3341-3348 (Pubitemid 39557497)
14. Facchiano AM, Facchiano A, Facchiano F (2003) Active Sequences Collection (ASC) database: a new tool to assign functions to protein sequences. Nucleic Acids Res 31: 379-382 (Pubitemid 36157285)
15. Mannucci E, Pala L, Ciani S et al (2005) Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 48: 1168-1172 (Pubitemid 40909653)
16. Ryskjaer J, Deacon CF, Carr RD et al (2006) Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 155: 485-493 (Pubitemid 44463956)
17. Takasawa W, Ohnuma K, Hatano R et al (2010) Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun 401: 7-12
18. Waltenberger J (2001) Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 49: 554-560 (Pubitemid 32146418)
19. Pala L, Ciani S, Dicembrini I et al (2010) Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions. Diabet Med 27: 691-695
20. Pala L, Mannucci E, Pezzatini A et al (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310: 28-31 (Pubitemid 37162757)
21. Meneilly GS, Demuth HU, McIntosh CH et al (2000) Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 17: 346-350 (Pubitemid 30353798)
22. McKillop AM, Duffy NA, Lindsay JR et al (2008) Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36) amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 79: 79-85
23. + progenitor cells. J Immunol 169: 7000-7008 (Pubitemid 36899288)
24. Proost P, Struyf S, Schols D et al (1998) Processing by CD26/ dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 432: 73-76 (Pubitemid 28360743)
25. Zemani F, Silvestre JS, Fauvel-Lafeve F et al (2008) Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 28: 644-650 (Pubitemid 351651342)
26. Sauve M, Ban K, Momen MA et al (2010) Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59: 1063-1073
27. Zaruba MM, Theiss HD, Vallaster M et al (2009) Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4: 313-323
28. Fadini GP, Boscaro E, Albiero M et al (2010) The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 33: 1607-1609
29. Boulbou MS, Koukoulis GN, Makri ED et al (2005) Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension. Int J Cardiol 98: 39-44 (Pubitemid 40169850)
30. Nakamura K, Yamagishi S, Adachi H et al (2008) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 76: 52-56
31. Lambeir AM, Scharpe S, de Meester I (2008) DPP4 inhibitors for diabetes-what next? Biochem Pharmacol 76: 1637-1643
32. Matheeussen V, Baerts L, de Meyer G et al (2011) Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 392: 189-198
33. Bjelke JR, Christensen J, Nielsen PF et al (2006) Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem J 396: 391-399 (Pubitemid 43837255)
34. Ajami K, Pitman MR, Wilson CH et al (2008) Stromal cellderived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett 582: 819-825
35. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl JMed 331: 1480-1487 (Pubitemid 24356306)
36. Butler JM, Guthrie SM, Koc M et al (2005) SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest 115: 86-93 (Pubitemid 40385508)